

## GLOBAL EQUITY ALLOCATION CLASS R6

## OVERVIEW

The GMO Global Equity Allocation Fund seeks to generate total return greater than that of the MSCI All Country World Index.

The philosophy that underlies all of GMO's Asset Allocation investment strategies is the belief that, at times and in the short term, the pricing of asset classes can deviate from true intrinsic value but mean reverts to appropriate valuation levels over a complete market cycle. Using GMO's 7-Year Asset Class Forecasts, the Fund seeks to allocate to areas of the global equity markets we believe are most attractively valued. Our approach combines the best of GMO's top-down Asset Allocation views and bottom-up equity research to identify mispricings at both the asset class and individual security levels. The Fund allocates to equity strategies that are actively managed by other GMO investment teams with expertise and experience in security selection within their respective markets.

## CUMULATIVE TOTAL RETURNS (USD, NET OF FEES, %)

|                     | MTD   | QTD   | YTD   | 2023  | 2022   | 2021  | 2020  | 2019  |
|---------------------|-------|-------|-------|-------|--------|-------|-------|-------|
| Class R6            | -3.95 | -3.95 | 9.75  | 22.19 | -17.01 | 14.98 | 17.67 |       |
| Class III           | -3.95 | -3.95 | 9.71  | 22.24 | -17.01 | 14.98 | 9.52  | 25.82 |
| Benchmark           | -2.24 | -2.24 | 16.00 | 22.20 | -18.36 | 18.54 | 16.25 | 26.60 |
| Alternate Benchmark | -2.24 | -2.24 | 16.00 | 22.20 | -18.36 | 18.54 | 16.25 | 26.60 |

## ANNUALIZED TOTAL RETURNS (USD, NET OF FEES, %)

|                     | 1 Year | 3 Years | 5 Years | 10 Years | ITD   |
|---------------------|--------|---------|---------|----------|-------|
| Class R6            | 25.57  | 4.07    | -       | -        | 10.00 |
| Class III           | 25.57  | 4.07    | 8.34    | 6.80     | 7.82  |
| Benchmark           | 32.79  | 5.51    | -       | -        | 11.93 |
| Alternate Benchmark | 32.79  | 5.51    | -       | -        | 11.93 |

## STANDARDIZED SEC RETURNS (USD, NET OF FEES, %)(AS OF 30-SEP-24)

|                     | 1 Year | 3 Years | 5 Years | 10 Years | ITD   |
|---------------------|--------|---------|---------|----------|-------|
| Class R6            | 26.41  | 6.39    | -       | -        | 11.27 |
| Class III           | 26.36  | 6.39    | 10.05   | 7.20     | 8.00  |
| Benchmark           | 31.76  | 8.09    | -       | -        | 12.79 |
| Alternate Benchmark | 31.76  | 8.09    | -       | -        | 12.79 |

Net of all fees and expenses after reimbursement by the Manager, but not transaction costs, if any. If certain expenses were not reimbursed, performance would be lower. **Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein. To obtain performance information to the most recent month-end, visit [www.gmo.com](http://www.gmo.com). Performance is shown for both the applicable share class and the representative share class in the Fund.**

## FACTS

|                       |             |
|-----------------------|-------------|
| Share Class           | Class R6    |
| Share Class Ticker    | GMADX       |
| Share Class Inception | 15-Jul-20   |
| Fund Inception        | 26-Nov-96   |
| Total Assets          | \$666mm USD |
| Benchmark             | MSCI ACWI + |
| Alternate Benchmark   | MSCI ACWI   |

## RISK PROFILE (5-YEAR TRAILING)

|                    |       |
|--------------------|-------|
| Alpha (Jensen's)   | -2.46 |
| Beta               | 0.97  |
| R Squared          | 0.91  |
| Sharpe Ratio       | 0.34  |
| Standard Deviation | 17.56 |

## ANNUAL EXPENSES (%)

|                     |      |
|---------------------|------|
| Net Expense Ratio   | 0.57 |
| Gross Expense Ratio | 0.60 |

**Net Expense Ratio reflects the reduction of expenses from fee reimbursements. The fee reimbursements will continue until at least June 30, 2025. Elimination of this reimbursement will result in higher fees and lower performance.**

**Gross Expense Ratio is equal to the Funds Total Annual Operating Expenses set forth in the Funds most recent prospectus dated June 30, 2024.**

## PORTFOLIO MANAGEMENT



**Ben Inker, CFA**  
Joined GMO in 1992  
BA, Yale University



**John Thorndike**  
Joined GMO in 2015  
AB, Bowdoin College

**Risks:** Risks associated with investing in the Fund may include: (1) Market Risk - Equities: The market price of equities may decline due to factors affecting the issuer, its industries, or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares. (2) Management and Operational Risk: The risk that GMO's investment techniques will fail to produce desired results, including annualized returns and annualized volatility. (3) Non-U.S. Investment Risk: The market prices of many non-U.S. securities (particularly of companies tied economically to emerging countries) fluctuate more than those of U.S. securities. Many non-U.S. markets (particularly emerging markets) are less stable, smaller, less liquid, and less regulated than U.S. markets, and the cost of trading in those markets often is higher than it is in U.S. markets. For a more complete discussion of these risks and others, please consult the Fund's Prospectus. **Performance Returns:** Returns shown for periods greater than one year are on an annualized basis. Annualized Returns may include the impact of purchase premiums and redemption fees. The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.

## GLOBAL EQUITY ALLOCATION CLASS R6

## PORTFOLIO ALLOCATIONS (%)

| <i>Asset Class</i>                | <i>Exposure</i> |
|-----------------------------------|-----------------|
| <b>EQUITY</b>                     | <b>100.0</b>    |
| US                                | 6.0             |
| Quality                           | 12.0            |
| Small Cap Quality                 | 5.1             |
| International Opportunistic Value | 11.0            |
| US Small Value                    | 3.1             |
| Japan Fundamental Value           | 6.0             |
| Developed ex-US                   | 23.0            |
| US Opportunistic Value            | 13.1            |
| Quality Cyclicals                 | 5.0             |
| Resource Equity                   | 3.9             |
| Emerging Markets                  | 9.8             |
| Emerging ex-China                 | 2.0             |

## CHARACTERISTICS

|                                     | <i>Portfolio</i> | <i>Benchmark</i> |
|-------------------------------------|------------------|------------------|
| Price/Earnings - Hist 1 Yr Wtd Mdn  | 16.4x            | 29.3x            |
| Price/Book - Hist 1 Yr Wtd Avg      | 1.6x             | 3.1x             |
| Price/Cash Flow - Hist 1 Yr Wtd Mdn | 12.0x            | 20.1x            |
| Return on Equity - Hist 1 Yr Mdn    | 14.9%            | 19.4%            |
| Market Cap - Wtd Mdn Bil            | 30.5 USD         | 115.8 USD        |
| Number of Equity Holdings           | 1148             | 2580             |

## TOP HOLDINGS

| <i>Company</i>                            | <i>Country</i> | <i>Sector</i>          | <i>%</i>    |
|-------------------------------------------|----------------|------------------------|-------------|
| Roche Holding AG                          | Switzerland    | Health Care            | 1.5         |
| Taiwan Semiconductor Manufacturing Co Ltd | Taiwan         | Information Technology | 1.5         |
| Alphabet Inc                              | United States  | Communication Services | 1.4         |
| Meta Platforms Inc                        | United States  | Communication Services | 1.2         |
| Apple Inc                                 | United States  | Information Technology | 1.0         |
| Microsoft Corp                            | United States  | Information Technology | 1.0         |
| Johnson & Johnson                         | United States  | Health Care            | 1.0         |
| Sanofi SA                                 | France         | Health Care            | 0.9         |
| GSK PLC                                   | United Kingdom | Health Care            | 0.8         |
| 3i Group PLC                              | United Kingdom | Financials             | 0.7         |
| <b>Total</b>                              |                |                        | <b>11.0</b> |

## MARKET CAP BAND EXPOSURES (\$B)

|                                | <i>Portfolio</i> | <i>Benchmark</i> |
|--------------------------------|------------------|------------------|
| Small (5.5 & Below)            | 19.9             | 3.1              |
| Small - Medium (5.5 To 16.4)   | 19.2             | 9.5              |
| Medium (16.4 To 43.4)          | 19.5             | 15.6             |
| Medium - Large (43.4 To 119.4) | 15.7             | 23.0             |
| Large (119.4 & Above)          | 25.7             | 48.8             |

## SECTORS (%)

| <i>Sector</i>          | <i>Portfolio</i> | <i>Benchmark</i> |
|------------------------|------------------|------------------|
| Communication Services | 6.2              | 7.9              |
| Consumer Discretionary | 13.2             | 10.5             |
| Consumer Staples       | 6.7              | 6.2              |
| Energy                 | 6.1              | 4.1              |
| Financials             | 21.6             | 16.6             |
| Health Care            | 11.5             | 10.6             |
| Industrials            | 13.4             | 10.6             |
| Information Technology | 14.8             | 24.8             |
| Materials              | 4.8              | 3.9              |
| Real Estate            | 0.8              | 2.2              |
| Utilities              | 1.0              | 2.7              |

## REGIONS (%)

| <i>Region</i>            | <i>Portfolio</i> | <i>Benchmark</i> |
|--------------------------|------------------|------------------|
| United States            | 40.7             | 65.2             |
| Europe ex UK (Developed) | 19.7             | 11.1             |
| Japan                    | 13.8             | 4.9              |
| Emerging                 | 13.0             | 10.4             |
| United Kingdom           | 6.0              | 3.2              |
| Other International      | 5.5              | 5.3              |
| Cash Equivalents         | 1.2              | 0.0              |

## TOP COUNTRIES (%)

| <i>Country</i> | <i>Portfolio</i> | <i>Benchmark</i> |
|----------------|------------------|------------------|
| United States  | 40.7             | 65.2             |
| Japan          | 13.8             | 4.9              |
| United Kingdom | 6.0              | 3.2              |
| France         | 4.9              | 2.4              |
| Taiwan         | 3.2              | 2.0              |
| Switzerland    | 2.8              | 2.1              |
| Spain          | 2.5              | 0.6              |
| China          | 2.4              | 2.8              |
| Netherlands    | 2.4              | 1.0              |
| Germany        | 2.3              | 2.0              |

# GLOBAL EQUITY ALLOCATION CLASS R6

## IMPORTANT INFORMATION

**Benchmark(s):** The MSCI ACWI (All Country World) + Index is an internally maintained benchmark computed by GMO, comprised of (i) the GMO Global Equity Index, an internally maintained benchmark computed by GMO, comprised of 75% S&P 500 Index and 25% MSCI ACWI ex-U.S. Index (MSCI Standard Index Series, net of withholding tax) through 5/31/2008 and (ii) the MSCI ACWI Index (MSCI Standard Index Series, net of withholding tax) thereafter. S&P does not guarantee the accuracy, adequacy, completeness or availability of any data or information and is not responsible for any errors or omissions from the use of such data or information. Reproduction of the data or information in any form is prohibited except with the prior written permission of S&P or its third party licensors. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. The MSCI ACWI (All Country World) Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of global developed and emerging markets. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder. Please visit <https://www.gmo.com/americas/benchmark-disclaimers/> to review the complete benchmark disclaimer notice.

**An investor should consider the fund's investment objectives, risks, charges and expenses before investing. This and other important information can be found in the funds prospectus. To obtain a prospectus please visit [www.gmo.com](http://www.gmo.com). Read the prospectus carefully before investing.**

The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.

## GLOSSARY

**Portfolio Allocations:** Weightings are as of the date indicated and are subject to change. The groups indicated above represent exposures determined pursuant to proprietary methodologies and are subject to change over time. Totals may vary due to rounding. Group weights under 1% are not reflected.

**Risk Statistics:** Risk profile data is net of fees. Alpha is a measure of risk-adjusted return. Beta is a measure of a portfolio's sensitivity to the market. R-Squared is a measure of how well a portfolio tracks the market. Sharpe Ratio is the return over the risk free rate per unit of risk. Std Deviation is a measure of the volatility of a portfolio.

**Sector Exposures:** The Global Industry Classification Standard (GICS) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. (S&P). Neither MSCI, S&P, nor any third party makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including of merchantability and fitness for a particular purpose. Neither MSCI, S&P, nor any third party shall have any liability for any damages of any kind relating to the use of GICS.

**Top Holdings:** Portfolio holdings are percent of equity. Where applicable, the top holdings are derived by looking through to the underlying funds in which the asset allocation funds invest and, where appropriate, individual security positions are aggregated. They are subject to change and should not be considered a recommendation to buy individual securities.

## ABOUT GMO

Founded in 1977, GMO is a global asset manager committed to delivering superior performance and advice to our clients. We are privately owned, which allows us to singularly focus on our sole business – achieving outstanding long-term client investment outcomes. Offering multi-asset, equity, fixed income, and alternative strategies, we invest with a long-term, valuation-based philosophical approach.

AMSTERDAM

BOSTON

LONDON

SAN FRANCISCO\*

SINGAPORE

SYDNEY

TOKYO\*\*

\*GMO's West Coast Hub is comprised of members of Investment, Global Client Relations, and other teams located in and around the Greater San Francisco area

\*\*Representative Office

[www.GMO.com](http://www.GMO.com)